Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
OpenAI in talks with Samsung to power AI features, report says
-
4
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
S. Korea not to attend Sado mine memorial: foreign ministry
-
8
South Korean military plans to launch new division for future warfare
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
Kolon Life Science seeks approval to market gene therapy for degenerative arthritis
By 황유미Published : July 11, 2016 - 08:59
[DISCLOSURE] Kolon Life Science (102940) announced on July 11 that it has filed for approval from the Ministry of Food and Drug Safety to market Invossa, a treatment for osteoarthritis.
Developed under the name Tissuegene-C, it is the first gene therapy to seek approval in Korea, and the first allogeneic cell therapy in the world. Invossa treats degenerative arthritis by injecting genetically modified cartilage cells and alleviates pains, slows down degeneration and improves cartilages, the company explained.
